Age Related Macular Degeneration Companies

Top Industry Leaders in the Age Related Macular Degeneration Market

Age-Related Macular Degeneration Key Companies Disclaimer: List of key companies in no particular order

October 2023: The Food and Drug Administration approved Endogena's medication for age-related macular degeneration. EA-2351 will be the subject of a clinical study for geographic atrophy by the business. Geographic atrophy (GA) is a severe type of age-related macular degeneration (AMD), and the FDA has approved an experimental new medication application from Endogena Therapeutics to treat it. Endogena will be allowed to move on with clinical testing of EA-2350 now that it has received FDA approval to do so. Among those aged 45 and up, AMD is the major cause of permanent visual loss and is estimated to afflict 9 percent of the population. GA is a persistent, progressive degeneration of the macula that occurs as a result of advanced AMD and can eventually cause permanent vision loss.

October 2023: Vabysmo (faricimab) was authorized by the U.S. Food and Drug Administration (FDA) in October 2023 for the treatment of macular edema caused by retinal vein occlusion (RVO), as stated by Roche. RVO joins neovascular or 'wet' age-related macular degeneration (nAMD) and diabetic macular edema (DME) as Vabysmo's indications. About 70 million individuals worldwide suffer from one of these three retinal diseases, making them major contributors to blindness. Vabysmo is a novel therapy for RVO that has the extra benefit of drying the retina, allowing patients to maintain or even enhance their eyesight. Hundreds of thousands of patients have been successfully treated, attesting to the safety and effectiveness of Vabysmo in both clinical studies and the real world.

List of Age-related macular degeneration Key companies in the market